DrugPatentWatch Database Preview

BOEHRINGER INGELHEIM Company Profile

« Back to Dashboard

What is the competitive landscape for BOEHRINGER INGELHEIM, and when can generic versions of BOEHRINGER INGELHEIM drugs launch?

BOEHRINGER INGELHEIM has forty-nine approved drugs.

There are ninety-three US patents protecting BOEHRINGER INGELHEIM drugs. There is one tentative approval on BOEHRINGER INGELHEIM drugs.

Summary for BOEHRINGER INGELHEIM

US Patents:	93
Tradenames:	40
Ingredients:	30
NDAs:	49
Patent Litigation for BOEHRINGER INGELHEIM:	See patent lawsuits for BOEHRINGER INGELHEIM
PTAB Cases with BOEHRINGER INGELHEIM as petitioner:	See PTAB cases with BOEHRINGER INGELHEIM as petitioner

Drugs and US Patents for BOEHRINGER INGELHEIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-002	Jul 12, 2013		RX	Yes	No	9,539,258
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011		RX	Yes	Yes	7,837,235		Y
Boehringer Ingelheim	MIRAPEX ER	pramipexole dihydrochloride	TABLET, EXTENDED RELEASE;ORAL	022421-002	Feb 19, 2010	AB	RX	Yes	No	8,679,533		Y
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-005	Jul 1, 1997	AB	RX	Yes	No	6,001,861

Expired US Patents for BOEHRINGER INGELHEIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-002	Jul 1, 1997	6,001,861
Boehringer Ingelheim	MICARDIS HCT	hydrochlorothiazide; telmisartan	TABLET;ORAL	021162-001	Nov 17, 2000	5,591,762
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-005	Jul 1, 1997	4,886,812
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-002	Jul 1, 1997	4,843,086

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	400 mg		2013-06-21
	Tablets	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg		2015-05-04
	Tablets	80 mg/12.5 mg and 40 mg/12.5 mg		2008-12-31
	Tablets	0.125 mg, 0.5 mg, 1 mg and 1.5 mg		2005-06-24
	Extended-release Capsules	25 mg and 200 mg		2007-02-01
	Tablets	0.75 mg		2008-07-31
	Capsules	eq. to 75 mg base and 150 mg base		2014-10-20
	Inhalation Powder Capsules	18 mcg		2018-05-11
	Extended-releaseTablets	2.5 mg/1000 mg 5 mg/1000 mg		2018-03-28
	Extended-release Tablets	2.25 mg and 3.75 mg		2011-07-26
	Tablets	20 mg, 30 mg and 40 mg		2017-07-12
	Tablets	20 mg, 40 mg and 80 mg		2006-12-26
	Tablets	80 mg/25 mg		2009-02-27
	Tablets	0.25 mg		2005-05-27
	Capsules	0.4 mg		2004-12-20
	Tablets	5 mg		2015-05-04
	Capsules	eq. to 110 mg base		2015-12-15
	Oral Suspension	7.5 mg/5 mL		2009-12-17
	Extended-release Tablets	0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg		2010-06-01

International Patents for BOEHRINGER INGELHEIM Drugs

Country	Document Number	Estimated Expiration
Denmark	1144386
Estonia	200200197
Cuba	23440
Taiwan	I500423

Supplementary Protection Certificates for BOEHRINGER INGELHEIM Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2014044	Lithuania		PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001-011 20110824
90035-4	Sweden		PRODUCT NAME: LINAGLIPTIN, DESS ENANTIOMERER OCH SALTER DAERAV; REG. NO/DATE: EU/1/11/707/001 20110824
2014005,C1345910	Lithuania		PRODUCT NAME: AFATINIBUM; REGISTRATION NO/DATE: EU/1/13/879/001-EU/1/13/879/012 20130925
0443983/03	Switzerland		PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Boehringer Ingelheim